When was PharmaReview founded?

PharmaReview was founded in 2011 and raised its 1st funding round within a year of its incorporation.

Where is PharmaReview located?

PharmaReview is headquartered in London, United Kingdom. It is registered at 2ND FLOOR BUILDING 7, CHISWICK PARK,CHISWICK HIGH ROAD,LONDON,ENGLAND,W4 5YG.

How many employees does PharmaReview have?

As of Mar 31, 2026, the latest employee count at PharmaReview is 29.

Is PharmaReview a funded company?

PharmaReview is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 01, 2011.

When was the latest funding round of PharmaReview?

PharmaReview's latest funding was a $***** PE round on Jul 05, 2021, with participation from 1 investor. Its primary sector is Services for Healthcare Providers. Globally, the Services for Healthcare Providers sector has seen $1.09B in funding in 2026 to date.

What is the annual revenue of PharmaReview?

Annual revenue of PharmaReview is between £10M and £50M as on Dec 31, 2024

Where does PharmaReview rank among its competitors?

PharmaReview ranks 9th amongst 47 active competitors, of which 6 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was NIMBLE Diagnostics, which secured $2.65M in Oct, 2023.

Who are the top competitors of PharmaReview?

PharmaReview's top competitors include Catalys Pacific, Orphalan and NIMBLE Diagnostics. Among them, NIMBLE Diagnostics secured the most recent funding round in October, 2023.

PharmaReview - 2026 Company Profile, Team, Funding, Competitors & Financials

PharmaReview is a late stage company based in London (United Kingdom), founded in 2011 by Tessa Pugh. It operates as a Provider of review pharmaceutical services for the lifesceince industry. PharmaReview has raised an undisclosed amount in funding from Bridgepoint Group. The company has 47 active competitors, including 6 funded and 9 that have exited. Its top competitors include companies like Catalys Pacific, Orphalan and NIMBLE Diagnostics.

Company Details

Website: pharmareview.com
Social
Email ID: *****@pharmareview.com
Phone Number: +44 **********
Registered Address: 2ND FLOOR BUILDING 7, CHISWICK PARK,CHISWICK HIGH ROAD,LONDON,ENGLAND,W4 5YG

Key Metrics

Founded Year

2011

Location

London, United Kingdom

Stage

Late Stage

Latest Funding Round

PE, Jul 05, 2021, $*****

Investors

Bridgepoint Group & 1 more

Ranked

9^th among 47 active competitors

Annual Revenue

£10M - £50M as on Dec 31, 2024

Employee Count

29 as on Mar 31, 2026

Similar Companies

Catalys Pacific & 46 more

View PharmaReview's full profile

PharmaReview is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PHARMAREVIEW LIMITED CIN: 7796206 , United Kingdom, Active	Oct 03, 2011	£10M - £50M (As on Dec 31, 2024)	73 (As on Dec 31, 2024)

PharmaReview has raised funding over 6 rounds. Its first funding round was on May 01, 2011. Its latest funding round was a PE round on Jul 05, 2021 for $*****. 1 investor participated in its latest round. PharmaReview has 2 institutional investors.

Here is the list of recent funding rounds of PharmaReview:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 05, 2021	6180356	PE	9686553	6692114	9996822	5340572
Mar 01, 2015	1874704	Grant (prize money)	3260264	2715754	4507219	HHS
Feb 15, 2015	5947885	Grant (prize money)	2399723	5169136	8333654	HHS

Access funding benchmarks and valuations. Sign up today!

View details of PharmaReview's funding rounds and investors

The founders of PharmaReview is Tessa Pugh.

Here are the details of PharmaReview's key team members:

Tessa Pugh: Co-Founder of PharmaReview.

View details of PharmaReview's Founder profiles and Board Members

PharmaReview's employee count trend

PharmaReview has 29 employees as of Mar 26. Here is PharmaReview's employee count trend over the years:

Uncover PharmaReview's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PharmaReview include Catalys Pacific, Orphalan and NIMBLE Diagnostics. Here is the list of Top 10 competitors of PharmaReview, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Catalys Pacific 2019, Cayman Islands, Unfunded	Provider of diagnostic healthcare investment services	-	-	42/100
2nd	Orphalan 2011, Paris (France), Funding Raised	Developer and provider of access to innovative treatments to patients with rare diseases	-	Advent Life Sciences, Kreos Capital & 1 others	41/100
3rd	NIMBLE Diagnostics 2022, Badalona (Spain), Seed	Developer of diagnostic device for the detection of cardiovascular conditions	$1.08M	Ship2B, Grow Venture Partners & 4 others	35/100
4th	Monarch Diagnostics 2019, Irvine (United States), Unfunded	Provider of diagnostic testing services	-	-	35/100
5th	Shine Spect Janesville (United States), Unfunded	Provider of diagnostic radiopharmaceutical products and artificial intelligence solutions	-	-	34/100
6th	Droplet 2015, Gurugram (India), Acquired	Provider of home pathology sample collection and diagnostic tests services	$227K	Tata 1mg	32/100
7th	Amber Pharmacy 2008, Singapore (Singapore), Acquired	Provider of customized approach to diagnosing and delivering specialty medications, with a patient-centric focus on convenient access, personalized care, and comprehensive support	-	-	31/100
8th	Nutrasource 2002, Guelph (Canada), Acquired	Provider of marketing services for healthcare, nutraceutical & pharmaceutical sector	-	Maxim Corporate Partners	31/100
9th	PharmaReview 2011, London (United Kingdom), Late Stage	Provider of review pharmaceutical services for the lifesceince industry	-	Bridgepoint Group, HHS	30/100
10th	Livivos 2018, San Diego (United States), Funding Raised	Provider of point-of-care liver disease diagnostics devices	-	Particular Ventures, HHS	30/100